The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has provided additional funding in the amount of USD 587,995 to its contract with US-based biotechnology company Chrysalis BioTherapeutics, Inc., bringing the total contract award to develop TP508 as a therapeutic for COVID-19 patients to USD 1.5m, the company said.
Chrysalis is developing regenerative drugs that target vascular endothelial and progenitor cells.
The company, located in Galveston, TX. TP508 (rusalatide acetate), is licensed from The University of Texas Medical Branch at Galveston, TX.
Although TP508 has shown potential efficacy in stimulating early tissue repair in human clinical trials, it is not yet FDA-approved and is currently only available for investigational use.
Research reported in this press release was in whole or part supported with federal funds from NIAID under contract number HHSN272201700011C.
The content is solely the responsibility of the authors and Chrysalis BioTherapeutics, Inc. and does not necessarily represent official views of the National Institutes of Health or The University of Texas Medical Branch.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary